Dr. Dinesh Khanna
@sclerodermaUM
Followers
3K
Following
2K
Media
346
Statuses
2K
👉University of Michigan Scleroderma Program leading the way through excellence in clinical care, teaching, & research #scleroderma tweets≠advice Follow≠endorse
Ann Arbor, MI
Joined July 2017
We've received very touching #sclerodermastories from patients & family. Read them all at the link below. Please consider supporting the Michigan Medicine Scleroderma Program on #GivingBlueday 11/27/18, at https://t.co/fdyuuD58PT … #medicineneedsvictors #victorsinthehouse #Rheum
9
16
49
Join us today at 12 pm for Grand Rounds on "Systemic Sclerosis: An Update" presented by @sclerodermaUM, professor in the Division of Rheumatology. Learn more: https://t.co/H8svS3VM1m
0
2
4
Delighted to present @UMIntMed grand rounds today at noon ET. Systemic Sclerosis- an update! Join at https://t.co/YndJldBcr8 Password: 606879
3
4
20
DID YOU KNOW? >30% of Systemic Sclerosis pts present without Raynauds!. Data from 2 large US cohorts, of SSc dx with puffy fingers/hands or other symptoms. Such patients presented with more severe skin and musculoskeletal disease. https://t.co/NP3KeUL5iX
1
6
25
Our first person Susan Chrysogelos who received CAR-T #scleroderma @UMIntMed @srfcure @scleroderma
https://t.co/tyhjqogXaI
#findcureforscleroderma
michiganmedicine.org
The CAR-T treatment has been used in cancer patients for years. Now the approach is being used for those with severe scleroderma to teach the body to fight the autoimmune disorder.
1
6
35
Bringing rheumatology closer to haematology. CAR-T therapy is showing tremendous promise in autoimmune conditions esp difficult to treat cases. #eular2025
Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
0
1
2
Novel Rx for #scleroderma ?adaptive ?B cells ?Tcells ?anti inflammatory ?costimulatory ?interferon ⬇️ ?anti fibrotic ?vascular remodelling 🤔all of above Hope for #SSc @Worldsclerofnd @SclerodermaCAN @scleroderma_sso @SclerodermaNews
@sclerodermaUM @FloridaRheums #FSR2025
0
4
12
If you screen (screening= pts who have no signs or symptoms suggestive of ILD), I screen regularly using
0
0
0
EULAR/ERS presented their ILD guidelines at #eular25. They recommended screening in all pts with #scleroderma, MCTD and IIM. ACR/ Chest guidelines recommended screening in high risk groups in these CTDs. Who do you screen with above CTD's? I will summarize data and share views
1
0
4
#CAR-T in active #scleroderma #diffuse open label @sclerodermaUM presented improvement in #nailfold #capillary patterns Suggesting #vascular recovery Hope is for lungs, skin and survival to improve but These are ▶️ Early days ?risk OP0338 #EULAR2025. @RheumNow @eular_org
3
12
54
🚨 Promising advances in #SystemicSclerosis at #EULAR2025! 🧬 CD19 CAR-T therapy shows encouraging efficacy in SLE, SSc & IIM with manageable safety ⚠️ 🔬 11+ ongoing Phase 2/3 trials in SSc(-ILD) targeting fibrosis, immunity, vasculopathy @sclerodermaUM
0
7
21
Considering Phase 3 trial in #scleroderma? if thinking about individual organ, consider this work presented at the #EULAR2025 and supported by SCTC and @NIH_NIAMS For composite endpoint, revised CRISS is being qualified by the regulatory agency
0
4
14
Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
1
18
52
Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS.
3
13
38
Excited to present WIN #scleroderma #eular2025. This slide highlights the opportunities in drug development in SSc. Come and join on Saturday 6/14 at 9 AM CET.
0
16
67
Work done by scleroderma program at @umichmedicine with @elizatsou and Johann Gudjonsson was licensed to Liferna Biotech! Exciting times to develop new therapies in #scleroderma and other fibrotic diseases! https://t.co/zKxcvoDd8l
liferna-biotech.com
Liferna pioneers RNA therapeutics, targeted drug delivery, disease-modifying therapy for autoimmune diseases, fibrotic diseases, systemic sclerosis, IPF.
0
0
4
Looking forward an exciting #eular2025. Exciting data on CAR-T in #scleroderma and invited lecture on WIN in systemic sclerosis. thanks for the invitation @eular_org
0
0
12
Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease https://t.co/FpTfNCkyjN Free copy available for download
tandfonline.com
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a common complication of systemic sclerosis (SSc), contributing significantly to morbidity and mortality. We aim to bridge knowl...
0
4
21